Related Experiment Video
Updated: Jan 29, 2026
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
1Tumor Immunology Laboratory, Department of Pulmonary Medicine and Immuno-Oncology Network Ghent, Ghent University Hospital, Ghent, Belgium.
Abstract:
More than many other fields in medicine, cancer vaccine development has been plagued by a wide gap between the massive amounts of highly encouraging preclinical data on one hand, and the disappointing clinical results on the other. It is clear now that traditional approaches from the infectious diseases' vaccine field cannot be borrowed as such to treat cancer. This review highlights some of the strategies developed to improve vaccine formulations for oncology, including research into more powerful or "smarter" adjuvants to elicit anti-tumoral cellular immune responses. As an illustration of the difficulties in translating smart preclinical strategies into real benefit for the cancer patient, the difficult road of vaccine development in lung cancer is given as example. Finally, an outline is provided of the combinatorial strategies that leverage the increasing knowledge on tumor-associated immune suppressive networks. Indeed, combining with drugs that target the dominant immunosuppressive pathway in a given tumor promises to unlock the true power of cancer vaccines and potentially offer long-term protection from disease relapse.
Insights
Cancer vaccine development faces challenges due to the gap between preclinical and clinical results. Novel strategies, including advanced adjuvants and combination therapies targeting immunosuppression, are crucial for effective cancer vaccines.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer vaccine development shows a significant gap between preclinical promise and clinical outcomes.
- Traditional infectious disease vaccine approaches are not directly applicable to cancer treatment.
Purpose of the Study:
- To review strategies for improving cancer vaccine formulations.
- To highlight challenges in translating preclinical findings to clinical benefit, using lung cancer as an example.
- To outline combinatorial approaches leveraging knowledge of tumor immunosuppression.
Main Methods:
- Review of current research in cancer vaccine development.
- Analysis of adjuvant strategies for eliciting anti-tumoral cellular immunity.
- Examination of combinatorial therapies targeting tumor-associated immune suppressive networks.
Main Results:
- Development of "smarter" adjuvants aims to enhance anti-tumoral immune responses.
- Lung cancer vaccine development illustrates the difficulties in clinical translation.
- Combining cancer vaccines with immunosuppression-targeting drugs shows promise.
Conclusions:
- Novel vaccine formulations and adjuvants are needed for oncology.
- Overcoming tumor-induced immunosuppression is key to unlocking cancer vaccine potential.
- Combination strategies offer a path toward long-term protection against cancer relapse.
Related Concept Videos
01:51Vaccinations
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:36Humoral Immune Responses
01:30Inflammatory Response I: Vascular and Cellular
01:40Cell-mediated Immune Responses
01:23Cells of the Adaptive Immune Response